MICHAEL HUANG: Open Payments
NPI 1548716004 · CONCORD, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$302 in 14 payments from 8 companies in 2025. Trend: 2023 $228 · 2024 $560 · 2025 $302
Food & beverage: $302
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 3 | $88 |
| Gilead Sciences, Inc. | 3 | $73 |
| Otsuka America Pharmaceutical, Inc. | 3 | $61 |
| E.R. Squibb & Sons, L.L.C. | 1 | $19 |
| ABBVIE INC. | 1 | $17 |
| Sage Therapeutics, LLC | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $14 |
Products named: SPRAVATO, ABILIFY ASIMTUFII, REXULTI, COBENFY, VRAYLAR, ZURZUVAE, Qelbree, CAPLYTA.
Industry payments across MA — which companies pay providers there.
